We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesNektar Therapeutics

Nektar Therapeutics

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
37.93 USD -0.51 ( 1.33%)
Last update at 2026-11-12T15:38:00Z
VOLUME
94614
Market Cap
2275.29M

Momentum Score

…

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
37.01
Low
38.32
High
52 Week Price Range
33.40
Low
109.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
38.44
Dividend Yield
-
Revenue TTM
54.59M
Revenue Per Share
2.25
Gross Profit TTM
54.59M
Debt / Equity
1.66
ROE
-35.76%
Net Debt
133.79M
ROCE
-60.84%
Diluted EPS TTM
-5.96

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -164.21M -119.20M -276.26M -364.98M -523.28M
Net income -164.08M -118.96M -276.06M -368.20M -523.84M
Selling general administrative 68.67M 76.75M 77.42M 92.33M 122.84M
Selling and marketing expenses - - 2.20M - -
Gross profit 55.23M 67.74M 53.48M 70.42M 77.01M
Reconciled depreciation 1.03M 4.39M 9.35M 13.03M 14.15M
Ebit -138.03M -91.09M -250.92M -240.24M -446.10M
Ebitda -137.00M -86.70M -243.11M -220.54M -453.80M
Depreciation and amortization 1.03M 4.39M 7.82M 19.70M -7.70M
Non operating income net other - - - - -29.86M
Operating income -130.77M -105.20M -137.43M -240.24M -446.10M
Other operating expenses 186.00M 203.62M 227.55M 332.29M 548.01M
Interest expense 26.18M 28.11M 25.33M 28.91M 47.31M
Tax provision -0.14M -0.24M 2.97M 3.21M 0.56M
Interest income 10.44M 14.50M 17.62M 6.67M 2.57M
Net interest income -15.75M -13.61M -8.05M -22.24M -44.74M
Income tax expense -0.14M -0.24M -0.20M 3.21M 0.56M
Total revenue 55.23M 98.43M 90.12M 92.06M 101.91M
Total operating expenses 186.00M 172.94M 190.90M 310.66M 523.11M
Cost of revenue 0.00M 30.69M 36.64M 21.64M 24.90M
Total other income expense net -33.44M -14.00M -138.83M -124.75M -77.18M
Net income from continuing ops -164.08M -118.96M -293.67M -368.20M -523.84M
Net income applicable to common shares - - - -368.20M -523.84M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 280.41M 303.85M 398.03M 710.60M 1117.19M
Other current assets 18.73M 4.46M 8.73M 15.81M 23.33M
Total liab 190.57M 243.11M 267.05M 343.96M 437.68M
Total stockholder equity 89.83M 60.74M 130.99M 366.64M 679.51M
Other current liab 22.27M 29.97M 22.16M 36.56M 58.01M
Common stock 0.00M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.00M 0.02M 0.02M 0.02M 0.02M
Retained earnings -3760.29M -3596.21M -3477.25M -3201.19M -2832.99M
Other liab - - - 162.93M 226.75M
Good will - - 0.00M 76.50M 76.50M
Other assets - - - 2.25M 2.74M
Cash 15.12M 44.25M 20.16M 88.23M 25.22M
Total current liabilities 53.54M 61.40M 51.27M 68.20M 85.20M
Net debt 133.79M 58.31M 210.24M 43.27M 117.96M
Short term debt 20.50M 19.87M 19.26M 18.67M 17.44M
Short long term debt total 148.91M 102.56M 230.40M 131.50M 143.18M
Other stockholder equity 3850.10M 3656.87M 3608.14M 3574.72M 3516.64M
Property plant equipment - - - 85.89M 177.53M
Total current assets 266.27M 261.29M 330.70M 545.97M 795.58M
Long term investments 3.49M 26.09M 25.82M 0.00M 64.83M
Net tangible assets - - - 290.14M 603.01M
Short term investments 230.64M 210.97M 283.45M 416.75M 708.74M
Net receivables 1.78M 1.61M 2.25M 5.98M 22.49M
Inventory - 0.00M 16.10M 19.20M 15.80M
Accounts payable 10.77M 11.56M 9.85M 12.98M 9.75M
Accumulated other comprehensive income 0.02M 0.06M 0.08M -6.91M -4.16M
Common stock total equity - - - - 0.02M
Retained earnings total equity - - - - -2832.99M
Non currrent assets other 5.65M 4.65M 4.64M 2.25M 2.74M
Non current assets total 14.14M 42.56M 67.33M 164.63M 321.61M
Capital lease obligations 85.75M 102.56M 117.78M 131.50M 143.18M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.33M 142.57M 162.19M 365.83M 217.77M
Change to liabilities - - - 2.04M -12.29M
Total cashflows from investing activities -1.20M 142.57M 139.56M 365.83M 202.78M
Total cash from financing activities 180.57M 42.12M 0.03M 1.51M 36.24M
Change to operating activities - - - -14.66M -22.67M
Net income -164.08M -118.96M -276.06M -368.20M -523.84M
Change in cash -29.14M 8.97M -52.95M 63.01M -173.74M
Begin period cash flow 44.25M 35.28M 88.23M 25.22M 198.96M
End period cash flow 15.12M 44.25M 35.28M 88.23M 25.22M
Total cash from operating activities -208.51M -175.71M -192.61M -304.01M -412.66M
Issuance of capital stock 180.85M 0.00M - - -
Depreciation -4.49M 4.39M 7.82M 13.03M 14.15M
Other cashflows from investing activities -0.70M 65.39M 1.25M - -
Change to inventory 0.00M 0.50M 0.70M -3.40M -0.51M
Change to account receivables 0.00M -3.04M 4.78M 16.51M 12.40M
Sale purchase of stock 0.00M -3.00M 0.00M - 33.24M
Other cashflows from financing activities 180.57M 15.00M 0.03M 1.51M 36.24M
Change to netincome - - - 50.67M 120.11M
Capital expenditures 0.17M 1.47M 0.86M 5.68M 14.99M
Change receivables - - - - 12.40M
Cash flows other operating - - - - 30.19M
Cash and cash equivalents changes - - - - -173.65M
Change in working capital -37.02M -6.24M -19.80M 0.49M -23.08M
Stock based compensation 12.65M 21.61M 33.39M 57.32M 94.67M
Other non cash items -15.58M -76.51M 62.19M -9.36M 17.41M
Free cash flow -208.68M -177.18M -193.47M -309.68M -427.65M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NKTR
Nektar Therapeutics		 -0.51
1.33%		 37.93 - 34.01 41.68 2.59 31.75 -6.50
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158

415 482 5300

https://www.nektar.com

63

Name Title Year Born
Mr. Howard W. Robin CEO, Pres & Director 1953
Mr. Mark A. Wilson Chief Legal Officer & Sec. 1972
Dr. Jonathan Zalevsky Ph.D. Sr. VP & Chief R&D Officer 1975
Mr. John P. Northcott Strategic Consulting Advisor 1978
Ms. Jillian B. Thomsen Chief Financial Officer 1966
Mr. Robert Bacci Sr. VP of HR & Facilities Operations NA
Ms. Jennifer Ruddock Chief Bus. Officer NA
Dr. Mary Tagliaferri L.Ac., M.D. Chief Devel. Officer 1966
Dr. Brian L. Kotzin M.D. Chief Medical Officer 1949
Dr. Kevin Brodbeck Ph.D. Sr. VP of Technical Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…